Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_4
2
50%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(2)
Other(1)

Detailed Status

Terminated2
Completed1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
33.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 42 (50.0%)

Trials by Status

completed125%
terminated250%
suspended125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_4

Ketamine-assisted Therapy for Advanced GI Cancer

NCT06077487
terminatedphase_4

Ketamine for Pain in the Emergency Department

NCT03896230
suspendedphase_2

A Study of Human Multi-Sensory Integration

NCT03498391
completedphase_1

Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine

NCT04485702

Clinical Trials (4)

Showing 4 of 4 trials
NCT06077487Phase 4

Ketamine-assisted Therapy for Advanced GI Cancer

Terminated
NCT03896230Phase 4

Ketamine for Pain in the Emergency Department

Terminated
NCT03498391Phase 2

A Study of Human Multi-Sensory Integration

Suspended
NCT04485702Phase 1

Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4